Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Feb 26;321(8):800-801.
doi: 10.1001/jama.2019.0015.

Management of Blood Cholesterol

Francis J Alenghat  1 , Andrew M Davis  1
Affiliations
Comment

Management of Blood Cholesterol

Francis J Alenghat et al. JAMA. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure
Figure
Major Recommendations for Management of Blood Cholesterol ASCVD indicates atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol. a Very high-risk ASCVD: multiple major ASCVD events (acute coronary syndrome in past year, prior myocardial infarction or cerebrovascular accident, peripheral artery disease with symptoms or procedure) or 11 major ASCVD event and multiple high-risk conditions (aged ≥65 years, diabetes, hypertension, chronic kidney disease, heart failure, smoking, prior coronary artery bypass graft surgery/percutaneous coronary intervention, persistent LDL-C ≥100 mg/dL). Using 10-year ASCVD risk calculator in primary prevention, high = ≥20%; intermediate = 7.5%−19.9%; borderline = 5%−7.4%; and low = <5%. b High intensity: atorvastatin, 40–80 mg/d; rosuvastatin, 20–40 mg/d. Moderate intensity: atorvastatin, 10–20 mg/d; rosuvastatin, 10 mg/d; simvastatin, 20–40 mg/d; pravastatin or lovastatin, 40 mg/d. Consider high-intensity statin in diabetes for patients aged 50 to 75 years with multiple high-risk conditions. c Reduction of LDL-C level is a secondary goal after reduction of LDL-C percentage is achieved. Consider additional agents (ezetemibe before PCSK9 inhibitors) if LDL-C goals are not met using maximum tolerated statin therapy. d Discuss risk enhancers such as family history of premature ASCVD, chronic inflammatory conditions, metabolic syndrome, South Asian ancestry, elevated lipoprotein(a), etc, as well as coronary artery calcium testing in select intermediate- and borderline-risk patients to potentially reclassify risk.
See this image and copyright information in PMC

Comment on

References

    1. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering. JAMA. 2018;319(15):1566–1579. - PMC - PubMed
    1. Wilson PWF, Polonsky TS, Miedema MD, et al. Systematic review for the 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/ NLA/PCNA guideline on the management of blood cholesterol [published online November10,2018]. JAm Coll Cardiol. doi:10.1016/j.jacc.2018.11.004 - DOI - PubMed
    1. Grundy SM, Stone NJ, Bailey AL, et al. 2018. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/ APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol [published online November 10,2018]. JAm Coll Cardiol. doi:10.1016/j.jacc.2018.11.003 - DOI - PubMed
    1. Doran B, Guo Y, Xu J, et al. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality. Circulation. 2014;130(7):546–553. - PubMed
    1. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059): 2532–2561. - PubMed

Substances